Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
Published: 03 December 2019
-
Views:
518 -
Likes:
7
-
Views:
518 -
Likes:
7
-
9m 54sPart 1 SGLT2 in HF Now and the Future Andrew JS Coats, Carolyn Lam
-
5m 9sPart 2 DAPA-HF Trial Design Rationale Felipe Martínez
-
8m 5sPart 3 SGLT2 beyond diabetes Lars H Lund
-
10m 15sPart 4 Guidelines, Recent Data & Future Practices Andrew JS Coats, Scott Solomon
Overview
The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.
Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
Learning Objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
- Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
- Assess the interrelationships linking diabetes, HF and CVD
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
More from this programme
Part 1
SGLT2 in HF Now and the Future
1 session | |
SGLT2 in HF Now and the Future | Watch now |
Part 2
DAPA-HF Trial Design Rationale
1 session | |
DAPA-HF Trial Design Rationale | Watch now |
Part 3
SGLT2 beyond diabetes
1 session | |
SGLT2 beyond diabetes | Watch now |
Part 4
Guidelines, Recent Data & Future Practices
Part 5
DAPA-HF Trial
1 session | |
DAPA-HF Trial | Watch now |
Part 6
Discussion with the DAPA-HF Trialist
Faculty Biographies
Frank Ruschitzka
Co-head of the Department of Cardiology
Professor Frank Ruschitzka, MD, FRCP (Edinburgh), FESC received his medical degree from the University of Gottingen in Germany in 1989. He specialized in internal medicine, nephrology and cardiology at the Universities of Gottingen and Zurich.
In 2001, he received the Cardiovascular Science Award of the Swiss Society of Cardiology as well as the Annual Award of the Swiss Society of Hypertension. In 2003, he was awarded the annual Gotz-Preis of the Medical Faculty of the University of Zurich for excellence in clinical medicine and research.
Professor Ruschitzka is President of the Heart Failure Association of the European Society of Cardiology and deputy editor of the European Heart Journal.